Merck & Company ( (MRK) ) has released its Q2 earnings. Here is a breakdown of the information Merck & Company presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Merck & Co., Inc., known as MSD outside the United States and Canada, is a leading biopharmaceutical company focused on innovative health solutions, including medicines and vaccines for both human and animal health. The company is headquartered in Rahway, New Jersey, and has a strong presence in the pharmaceutical industry with a diverse portfolio of products and a commitment to research and development.
In its second-quarter 2025 financial results, Merck reported total worldwide sales of $15.8 billion, marking a 2% decrease compared to the same period in 2024. Despite this decline, the company saw growth in key areas such as oncology, with KEYTRUDA sales increasing by 9%, and animal health, which grew by 11%. However, sales of GARDASIL/GARDASIL 9 experienced a significant decline of 55%, primarily due to lower demand in China.
Key financial metrics for the quarter included a GAAP EPS of $1.76 and a non-GAAP EPS of $2.13, both of which were impacted by a charge related to the closing of a license agreement with Hengrui Pharma. Merck also announced a strategic acquisition of Verona Pharma, expected to close in the fourth quarter of 2025, and a multiyear optimization initiative aimed at achieving $3.0 billion in annual cost savings by 2027.
Looking ahead, Merck has narrowed its full-year 2025 financial outlook, with expected worldwide sales between $64.3 billion and $65.3 billion and a non-GAAP EPS range of $8.87 to $8.97. The company remains focused on strategic growth areas and is confident in its ability to deliver value for shareholders and patients through continued innovation and portfolio transformation.